Impact of early molecular tumour board inclusion on treatment outcomes in neuroendocrine neoplasms: A retrospective double-centre study

#4499

Introduction: The treatment of neuroendocrine neoplasms (NENs) is particularly challenging due to the limited availability of standard therapies. While personalised approaches are revolutionising many areas of oncology, their progress in the field of NENs has been comparatively slower. The integration of molecular tumour boards (MTBs) into clinical practice represents a major advance in oncology, even for rare entities such as NENs.

Aim(s): This study aims to evaluate the impact of MTB inclusion and recommended targeted therapies in patients with NENs in a real-world setting.

Materials and methods: We conducted a retrospective analysis of 92 patient cases with NEN which were discussed at the MTBs of the University Hospital Freiburg and the Technical University Munich between 2017 and 2024. Disease characteristics, genetic profiles, therapy recommendations, implemented therapies and patient outcome were collected. Molecular testing was performed by different techniques including NGS and WES.

Conference:

Presenting Author: Klaas L

Authors: Barsch M, Graessel L, Metzger P, Klaas L, Schulz L,

Keywords: Neuroendocrine neoplasm, Molecular Tumour Board, personalised medicine, precision oncology, targeted therapy,